Logen FDA Approved Drugs
BOSULIF [Bosutinib MonohydrateC26H29Cl2N5O3H2O]
RX
- eq 100mg base (oral tablet)
eq 500mg base (oral tablet)
Pf Prism CvSep 4, 2012
- A method of treating a neoplasm.
- A method of treating chronic myelogenous leukemia.
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE [Atropine Sulfate2C17H23NO3H2OH2O4S : Diphenoxylate HydrochlorideC30H32N2O2ClH]
RX
- 0.025mg/5ml : 2.5mg/5ml (oral solution)
0.025mg : 2.5mg (oral tablet)
West-ward Pharms IntMay 3, 1982
Ani Pharms IncApproved Prior To Jan 1, 1982
LannettApproved Prior To Jan 1, 1982
MylanApproved Prior To Jan 1, 1982
Par PharmMay 2, 2000
Ani Pharms IncApproved Prior To Jan 1, 1982
LannettApproved Prior To Jan 1, 1982
MylanApproved Prior To Jan 1, 1982
Par PharmMay 2, 2000
ICLUSIG [Ponatinib HydrochlorideC29H27F3N6OClH]
RX
- eq 15mg base (oral tablet)
eq 30mg base (oral tablet)
eq 45mg base (oral tablet)
AriadDec 14, 2012
- A method for the treatment of leukemias.
- A method for treating acute lymphoblastic leukemia.
- A method for treating chronic myeloid leukemia.
- A method for treating leukemia resulting from a mutation in the bcr-abl kinase domain.
- A method for treating philadelphia chromosome positive acute lymphoblastic leukemia.
- A method of treating chronic myelogenous leukemia.
LOMOTIL [Atropine Sulfate2C17H23NO3H2OH2O4S : Diphenoxylate HydrochlorideC30H32N2O2ClH]
RX
- 0.025mg : 2.5mg (oral tablet)
Gd Searle LlcApproved Prior To Jan 1, 1982
MYFORTIC [Mycophenolic AcidC17H20O6]
RX
- 180mg (oral tablet, delayed release)
360mg (oral tablet, delayed release)
NovartisFeb 27, 2004
- Prophylaxis of organ rejection in patients receiving allogeneic renal transplants.
SPRYCEL [DasatinibC22H26ClN7O2SH2O]
RX
- 100mg (oral tablet)
140mg (oral tablet)
20mg (oral tablet)
50mg (oral tablet)
70mg (oral tablet)
80mg (oral tablet)
Bristol Myers SquibbMay 30, 2008
- A method for the treatment of a protein tyrosine kinase-associated disorder.
- A method for the treatment of cancer.
- A method for treatment of a cancer, wherein the cancer is chronic myelogenous leukemia.
SYNRIBO [Omacetaxine MepesuccinateC29H39NO9]
RX
- 3.5mg/vial (subcutaneous powder)
Teva Pharms IntlOct 26, 2012
- Treatment of leukemia.
- Treatment of patients with tyrosine kinase inhibitor (tki) resistant or intolerant chronic myeloid/myelogenous leukemia (cml).
TRISENOX [Arsenic TrioxideAs2O3]
RX
- 1mg/ml (injection injectable)
CephalonSep 25, 2000
- Treatment of acute promyelocytic leukemia (apl) in patients whose apl is characterized by the presence of the (15;17) translocation or pml/rar-alpha gene expression.
- Treatment of acute promyelocytic leukemia (apl).
- Treatment of acute promyelogenous leukemia (apl).
WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.